All Articles

Subanalysis of the phase 3 TOPAZ-1 trial found that durvalumab plus gemcitabine/cisplatin showed efficacy as a treatment regimen in patients with biliary tract cancer regardless of primary tumor location.

Early data from the ReFocus trial indicated that RLY-4008 may be an effective new treatment for patients with cholangiocarcinoma harboring FGFR2 fusions or rearrangements.

NEO-GAP investigators found neoadjuvant gemcitabine/cisplatin/nab-paclitaxel combination to be feasible and safe prior to curative-intent surgical resection in patients with intrahepatic cholangiocarcinoma.

The FIDES-01 clinical trial showed encouraging preliminary results for derazantinib as a second-line treatment in patients with intrahepatic cholangiocarcinoma harboring FGFR2 alterations.

Despite differences in baseline prognostic characteristics identified by the regional analysis of the TOPAZ-1 study, outcomes between the regions were generally similar.

Assessment of patient-reported outcomes revealed no clinically meaningful detriment occurred with the addition of durvalumab to gemcitabine/cisplatin in advanced biliary tract cancers.

Derazantinib was found to provide clinical benefit in patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 mutations or amplifications.

Analysis of the phase 3 ABC-06 trial revealed limited prognostic utility of the tumor marker CA19.9 after initiation of FOLFOX.

A comparison of clinical trials found progression-free survival with futibatinib to be significantly greater compared with chemotherapy and that trials favor futibatinib over pemigatinib for all efficacy parameters.

Immune-related adverse events in the TOPAZ-1 trial were more common in the durvalumab arm, had a variable time to onset, and were associated with improved overall survival.